A team at the University of Macau aimed to develop a novel peptide targeting the tumor necrosis factor (TNF)-TNFR2 interaction as a selective regulatory T cell (Treg) stimulator. Through phage display ...
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and ...
Siemens Healthineers AG became the latest company to sign a licensing agreement with Alzpath Inc. to use its pTau217 antibody ...
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies. Harbour is getting about $90 million up ...
Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene ...
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European ...
Much has been made of the recent skyrocketing of Medicare spending on skin substitutes, but a new enforcement action by the U.S. Department of Justice might help to explain some of those spending ...
The U.S. FDA announced Dec. 15 that it will take a more relaxed approach regarding the use of real-world evidence (RWE) in ...
Nchroma Bio Inc. has received a certificate for clinical trial in Hong Kong to initiate a first-in-human phase I/II trial of ...
Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with ...
The U.S. CDC has adopted the recommendations of its Advisory Committee for Immunization Practices (ACIP) regarding the hepatitis B virus (HBV) vaccine scheduling for infants, determining that ...
Gene editing can repair mutations that prematurely halt protein synthesis, resulting in incomplete peptides that cause various diseases. However, other approaches achieve the same effect without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results